Hemispherx BioPharma (HEB) Financials

View full company profile

$13.9 M

HEB Mkt cap, 14-Jun-2018

$56 K

Hemispherx BioPharma Revenue Q1, 2018

Hemispherx BioPharma Net income (Q1, 2018)-2.7 M

Hemispherx BioPharma EBIT (Q1, 2018)-2.6 M

Hemispherx BioPharma Cash, 31-Mar-20184 M

Hemispherx BioPharma Financials

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Revenue	150 k	197 k	133 k	92 k
Revenue growth, %		31%	(32%)	(31%)
R&D expense	8.4 m	9 m	8 m	5.1 m
General and administrative expense	7.7 m	9.1 m	7.1 m	7.7 m
Operating expense total	16.1 m	18 m	15.2 m	12.8 m
EBIT	(17.2 m)	(19.1 m)	(16.7 m)	(13.8 m)
EBIT margin, %	(11445%)	(9695%)	(12519%)	(15004%)
Interest expense	16 k	11 k	3 k
Net Income	(16.2 m)	(17.5 m)	(15.2 m)	(7.5 m)

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017	Q1, 2018
Revenue	36 k	45 k	36 k	47 k	23 k	39 k	15 k	22 k	84 k	90 k	56 k
R&D expense	2.3 m	1.9 m	2.7 m	2.4 m	2 m	1 m	900 k	1.3 m	1.4 m	787 k	855 k
General and administrative expense	2.5 m	2.2 m	1.9 m	2 m	1.7 m	2.4 m	1.6 m	1.6 m	1.7 m	1.6 m	1.6 m
Operating expense total	4.8 m	4.1 m	4.6 m	4.4 m	3.7 m	3.5 m	2.5 m	3 m	3.1 m	2.7 m	2.6 m
Depreciation and amortization										739 k
EBIT	(5.1 m)	(4.3 m)	(4.9 m)	(4.9 m)	(4 m)	(3.7 m)	(2.8 m)	(3.2 m)	(3.2 m)	(2.7 m)	(2.6 m)
EBIT margin, %	(14125%)	(9620%)	(13675%)	(10428%)	(17317%)	(9433%)	(18760%)	(14664%)	(3858%)	(2947%)	(4589%)
Interest expense	3 k	3 k	2 k		1 k
Interest income											4 k
Net Income	(8.8 m)	(13 m)	(3.4 m)	(8.3 m)	(12.1 m)	(2.2 m)	(3.5 m)	(6.3 m)	(2.8 m)	(1.3 m)	(2.7 m)

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Cash	803 k	2.2 m	2.1 m	2.4 m
Accounts Receivable
Inventories		399 k	335 k
Current Assets	18.6 m	16.5 m	10.6 m	6.9 m
PP&E	5.1 m	4.6 m	11.2 m	9.5 m
Total Assets	31.9 m	29.4 m	22.8 m	18.9 m
Accounts Payable	1.3 m	2.1 m	1.2 m	887 k
Short-term debt
Current Liabilities	2.5 m	4.4 m	2.4 m	2.4 m
Long-term debt
Additional Paid-in Capital	289.6 m	302.7 m	313.2 m	316 m
Retained Earnings	(260.3 m)	(277.8 m)	(293 m)	(300.5 m)
Total Equity			20.4 m	15.5 m
Financial Leverage			1.1 x	1.2 x

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017	Q1, 2018
Cash	2.6 m	1.3 m	2.9 m	1.8 m	1.2 m	1 m	1.5 m	4.5 m	776 k	503 k	4 m
Accounts Receivable									41 k	42 k	29 k
Inventories										626 k
Current Assets	20.5 m	17.7 m	17.9 m	17.1 m	14 m	9.5 m	10.7 m	9.3 m	5.2 m	3.7 m	5.7 m
PP&E	4.8 m	4.7 m	11.8 m	11.7 m	11.5 m	10.9 m	10.1 m	9.8 m	9.3 m	8.8 m	8.4 m
Total Assets	33.5 m	30.6 m	30.8 m	29.9 m	26.5 m	21.5 m	21.9 m	21.6 m	16.9 m	14.7 m	16.3 m
Accounts Payable	1.5 m	2.4 m	2.3 m	1.6 m	1.5 m	1.4 m	1.4 m	1 m	927 k	460 k	850 k
Short-term debt										1.5 m
Current Liabilities	4.2 m	4.3 m	3.8 m	3.1 m	3.3 m	3.1 m	4.4 m	2.4 m	2.6 m	2.2 m	2.7 m
Total Debt										1.5 m
Additional Paid-in Capital	298.2 m	299.6 m	308 m	312.8 m	313.2 m	313.3 m	313.6 m	315.9 m	316.2 m	316.7 m	321.6 m
Retained Earnings	(269.1 m)	(273.3 m)	(281.2 m)	(286.1 m)	(289.9 m)	(295.2 m)	(296.5 m)	(299.3 m)	(303.3 m)	(306.8 m)	(311.5 m)
Total Equity				26.8 m	23.2 m	18.4 m	17.5 m	16.6 m	12.9 m	10 m	10.2 m
Financial Leverage				1.1 x	1.1 x	1.2 x	1.3 x	1.3 x	1.3 x	1.5 x	1.6 x

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016
Net Income	(16.2 m)	(17.5 m)	(15.2 m)	(7.5 m)
Depreciation and Amortization	671 k	665 k	941 k	1.1 m
Accounts Receivable
Inventories			(1.3 m)
Accounts Payable	(617 k)	869 k	(196 k)	(326 k)
Cash From Operating Activities	(16.8 m)	(13.9 m)	(16.1 m)	(7.4 m)
Cash From Investing Activities	22.3 m	2.5 m	6.4 m	2.9 m
Cash From Financing Activities	(6.8 m)	12.8 m	9.7 m	4.8 m

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018
Net Income	(8.8 m)	(13 m)	(3.4 m)	(8.3 m)	(12.1 m)	(2.2 m)	(3.5 m)	(6.3 m)	(2.8 m)	(2.7 m)
Depreciation and Amortization	332 k	500 k	180 k	458 k	663 k	300 k	576 k	854 k	261 k	216 k
Accounts Receivable									(41 k)	(6 k)
Inventories			(480 k)	(1 m)	(1.3 m)
Accounts Payable	238 k	1.2 m	236 k	189 k	97 k	182 k	178 k	(202 k)	103 k	245 k
Cash From Operating Activities	(6.2 m)	(9.9 m)	(4.3 m)	(9.2 m)	(12.7 m)	(1 m)	(2.3 m)	(5.3 m)	(3 m)	(2.5 m)
Cash From Investing Activities	(420 k)	651 k	(192 k)	(355 k)	2.1 m	(60 k)	1.6 m	2.9 m	486 k	1 m
Cash From Financing Activities	8.4 m	9.7 m	5.2 m	9.3 m	9.7 m	1 k	162 k	4.7 m	875 k	4.1 m

Report incorrect company information

View Hemispherx BioPharma profile

Competitors

Health - Public

Health - Public

Ironwood Pharmaceuticals

Health - Public

Neurocrine Biosciences

Health - Public

Compare competitors